Hakutulokset - Saremi, Aramesh

Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT) Tekijä Saremi, Aramesh, Bahn, Gideon, Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT) Tekijä Saremi, Aramesh, Bahn, Gideon D., Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial Tekijä Giorgino, Francesco, Shaunik, Alka, Liu, Minzhi, Saremi, Aramesh

Hae kokoteksti Hae kokoteksti Hae kokoteksti

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT) Tekijä Koska, Juraj, Saremi, Aramesh, Bahn, Gideon, Yamashita, Shizuya, Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration... Tekijä Gautier, Thibault, Silwal, Rupesh, Saremi, Aramesh, Boss, Anders, Breton, Marc D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L Tekijä Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L Tekijä Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L Tekijä Blonde, Lawrence, Berard, Lori, Saremi, Aramesh, Huang, Yao, Aroda, Vanita R., Raccah, Denis

Hae kokoteksti Hae kokoteksti Hae kokoteksti

The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial Tekijä Saremi, Aramesh, Schwenke, Dawn C., Bahn, Gideon, Ge, Ling, Emanuele, Nicholas, Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study Tekijä Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C., Bahn, Gideon, Beisswenger, Paul J., Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study Tekijä Morea, Nicola, Retnakaran, Ravi, Vidal, Josep, Aroda, Vanita R., Liu, Minzhi, Saremi, Aramesh, Giorgino, Francesco

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT) Tekijä Saremi, Aramesh, Moritz, Thomas E., Anderson, Robert J., Abraira, Carlos, Duckworth, William C., Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance Tekijä Hu, Xia, Reaven, Peter D., Saremi, Aramesh, Liu, Ninghao, Abbasi, Mohammad Ali, Liu, Huan, Migrino, Raymond Q.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Association Between IL-6 and the extent of Coronary Atherosclerosis in The Veterans Affairs Diabetes Trial (VADT) Tekijä Saremi, Aramesh, Anderson, Robert J., Luo, Ping, Moritz, Thomas E., Schwenke, Dawn C., Allison, Mathew, Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Quantification of LVEF≤35% misclassification by 2D-echocardiography as compared to cardiac magnetic resonance in coronary artery disease: implications for AICD therapy Tekijä Parrington, Diane J, Saremi, Aramesh, Girotra, Sudhakar V, Dev, Sandesh, Oh, Charles, Scott, Cynthia L, Migrino, Raymond Q

Hae kokoteksti Hae kokoteksti

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes Tekijä Koska, Juraj, Saremi, Aramesh, Howell, Scott, Bahn, Gideon, De Courten, Barbora, Ginsberg, Henry, Beisswenger, Paul J., Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Hepatic Fat and Inflammation in Type 2 Diabetes Tekijä Saremi, Aramesh, Allison, Matthew, Ditomasso, Dominic, Ge, Ling, Anderson, Robert, Moritz, Tom E., Duckworth, William, Abraira, Carlos, Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score... Tekijä Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Explorat... Tekijä Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors Tekijä Saremi, Aramesh, Schwenke, Dawn C., Buchanan, Thomas A., Hodis, Howard N., Mack, Wendy J., Banerji, MaryAnn, Bray, George A., Clement, Stephen C., Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A., Reaven, Peter D.

Hae kokoteksti Hae kokoteksti Hae kokoteksti